Clinical Trial

A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-08
Trial Details
NCT Number NCT07661537
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions B-cell Non-Hodgkin Lymphoma
Enrollment 90 participants
Start Date 2026-07-23
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07